We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter's (BAX) ST Set Receives FDA Nod, to Boost Patient Outcome
Read MoreHide Full Article
Baxter International Inc. (BAX - Free Report) recently received the FDA’s 510(k) clearance for its ST Set used in continuous renal replacement therapy (“CRRT”). The system is expected to offer additional options to provide CRRT for patients in an acute care environment.
The ST Set, a pre-connected, disposable, extracorporeal (outside the body) circuit, offers blood purification via a semi-permeable membrane and is to be used with the PrisMax or Prismaflex control units (monitors). It has been available to U.S. customers since August 2020 after the receipt of the FDA’s Emergency Use Authorization to provide CRRT to treat patients in an acute care environment during the pandemic. Presently, the ST Set is being used across countries in Europe, Asia Pacific, and North and South America.
With the latest regulatory clearance, Baxter’s Renal Care business is expected to gain a solid foothold in the global arena.
Significance of the Approval
Per management, the ST Set has been playing a crucial role in boosting the availability of CRRT sets, which have been in high demand during the pandemic. The latest clearance, which will provide the ST Set to U.S. healthcare providers and hospitals on a permanent basis, will likely help in broadening access to CRRT for patients with acute kidney injury (“AKI”).
It is worth mentioning that AKI is a sudden decrease in kidney function that occurs over a period of certain hours to days, often resulting from illness, trauma or infection. The sudden loss of kidney function leads to the accumulation of toxins and fluid in blood which, if left untreated, may turn fatal. Further, AKI is an increasingly common complication of acute illnesses in intensive care units and hospitals, and is one of many complications affecting COVID-19 patients.
Industry Prospects
Per a report by Research and Markets, the global hemodialysis market was valued at $78.30 billion in 2019 and is estimated to reach $116.66 billion by 2030 at a CAGR of 3.6%. Factors like rising incidences of renal issues, growing cases of diabetes and hypertension, and shortage of kidney donors are likely to drive the market.
Given the market potential, the latest FDA approval is expected to provide a significant boost to Baxter’s business globally.
Notable Developments
In March, Baxter announced a long-term strategic partnership with Digital Diagnostics to advance diabetic retinopathy detection. The tie-up is aimed at helping front-line care providers deliver better quality of care and improve care outcomes.
The same month, the company announced new data indicating that the use of its Sharesource remote patient management platform with an automated peritoneal dialysis cycler may improve the clinical effectiveness of home kidney patients’ care by extending their time on therapy by 3.4 months.
In February, BAX announced its fourth-quarter 2021 financial results, wherein it registered a robust uptick in worldwide sales. The company also recorded solid performances across its three geographic segments, along with strong growth in its legacy businesses led by BioPharma Solutions.
Price Performance
Shares of the company have lost 9.7% in the past year compared with the industry’s 15.7% fall. The S&P 500 has risen 11.5% in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Baxter carries a Zacks Rank #3 (Hold).
A few stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , Edwards Lifesciences Corporation (EW - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 37.5% against the industry’s 54.4% fall over the past year.
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 13.9%. EW’s earnings surpassed estimates in three of the trailing four quarters, the average surprise being 6.5%.
Edwards Lifesciences has gained 42.9% compared with the industry’s 1.2% growth over the past year.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2.
Henry Schein has gained 26.9% compared with the industry’s 8.8% growth over the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Baxter's (BAX) ST Set Receives FDA Nod, to Boost Patient Outcome
Baxter International Inc. (BAX - Free Report) recently received the FDA’s 510(k) clearance for its ST Set used in continuous renal replacement therapy (“CRRT”). The system is expected to offer additional options to provide CRRT for patients in an acute care environment.
The ST Set, a pre-connected, disposable, extracorporeal (outside the body) circuit, offers blood purification via a semi-permeable membrane and is to be used with the PrisMax or Prismaflex control units (monitors). It has been available to U.S. customers since August 2020 after the receipt of the FDA’s Emergency Use Authorization to provide CRRT to treat patients in an acute care environment during the pandemic. Presently, the ST Set is being used across countries in Europe, Asia Pacific, and North and South America.
With the latest regulatory clearance, Baxter’s Renal Care business is expected to gain a solid foothold in the global arena.
Significance of the Approval
Per management, the ST Set has been playing a crucial role in boosting the availability of CRRT sets, which have been in high demand during the pandemic. The latest clearance, which will provide the ST Set to U.S. healthcare providers and hospitals on a permanent basis, will likely help in broadening access to CRRT for patients with acute kidney injury (“AKI”).
It is worth mentioning that AKI is a sudden decrease in kidney function that occurs over a period of certain hours to days, often resulting from illness, trauma or infection. The sudden loss of kidney function leads to the accumulation of toxins and fluid in blood which, if left untreated, may turn fatal. Further, AKI is an increasingly common complication of acute illnesses in intensive care units and hospitals, and is one of many complications affecting COVID-19 patients.
Industry Prospects
Per a report by Research and Markets, the global hemodialysis market was valued at $78.30 billion in 2019 and is estimated to reach $116.66 billion by 2030 at a CAGR of 3.6%. Factors like rising incidences of renal issues, growing cases of diabetes and hypertension, and shortage of kidney donors are likely to drive the market.
Given the market potential, the latest FDA approval is expected to provide a significant boost to Baxter’s business globally.
Notable Developments
In March, Baxter announced a long-term strategic partnership with Digital Diagnostics to advance diabetic retinopathy detection. The tie-up is aimed at helping front-line care providers deliver better quality of care and improve care outcomes.
The same month, the company announced new data indicating that the use of its Sharesource remote patient management platform with an automated peritoneal dialysis cycler may improve the clinical effectiveness of home kidney patients’ care by extending their time on therapy by 3.4 months.
In February, BAX announced its fourth-quarter 2021 financial results, wherein it registered a robust uptick in worldwide sales. The company also recorded solid performances across its three geographic segments, along with strong growth in its legacy businesses led by BioPharma Solutions.
Price Performance
Shares of the company have lost 9.7% in the past year compared with the industry’s 15.7% fall. The S&P 500 has risen 11.5% in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Baxter carries a Zacks Rank #3 (Hold).
A few stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , Edwards Lifesciences Corporation (EW - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 37.5% against the industry’s 54.4% fall over the past year.
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 13.9%. EW’s earnings surpassed estimates in three of the trailing four quarters, the average surprise being 6.5%.
Edwards Lifesciences has gained 42.9% compared with the industry’s 1.2% growth over the past year.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2.
Henry Schein has gained 26.9% compared with the industry’s 8.8% growth over the past year.